Colloidal properties of biodegradable nanoparticles influence interaction with amyloid-β peptide

被引:14
作者
Brambilla, Davide [1 ]
Souguir, Hayfa [1 ]
Nicolas, Julien [1 ]
Mackiewicz, Nicolas [1 ]
Verpillot, Romain [1 ]
Le Droumaguet, Benjamin [1 ]
Taverna, Myriam [1 ]
Couvreur, Patrick [1 ]
Andrieux, Karine [1 ]
机构
[1] Univ Paris Sud, Fac Pharm, Lab Physicochim Pharmacotechnie & Biopharm, UMR CNRS 8612, F-92296 Chatenay Malabry, France
关键词
Alzheimer's disease; Nanoparticles; Surface properties; Amyloid-beta peptide;
D O I
10.1016/j.jbiotec.2011.07.020
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the extracellular deposition of amyloid-beta peptides (A beta). During the past few years, promising approaches based on nanotechnologies have emerged to alter A beta aggregation and its related toxicity. This study aims to investigate the influence of the nanoparticle colloidal properties over the interaction with A beta peptide 1-42 (A beta(1-42)). Using capillary electrophoresis with laser-induced fluorescence detection, it was shown that biodegradable poly(ethylene glycol)-block-polylactide (PEG-b-PLA) nanoparticles were able to interact with A beta(1-42) peptide leading to its uptake in rather short time periods. In addition, we highlighted the crucial role of the nanocarrier colloidal properties on the uptake kinetics. Whereas nanoparticles stabilized by sodium cholate (lower size and higher negative surface charge) gave optimum uptake kinetics, nanoparticles stabilized with others surfactants presented lower interactions. In contrast, PEG density seemed to have no influence on the interaction when sodium cholate was used for the preparation. This study intends to give new insights into A beta(1-42) peptide interaction with nanoparticulate systems by helping to determine suitable nanoparticle characteristics regarding forthcoming therapeutic strategies against AD. (C) 2011 Elsevier B. V. All rights reserved.
引用
收藏
页码:338 / 340
页数:3
相关论文
共 10 条
[1]   Protein aggregation diseases: pathogenicity and therapeutic perspectives [J].
Aguzzi, Adriano ;
O'Connor, Tracy .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) :237-248
[2]   An orally delivered small-molecule formulation with antiangiogenic and anticancer activity [J].
Benny, Ofra ;
Fainaru, Ofer ;
Adini, Avner ;
Cassiola, Flavia ;
Bazinet, Lauren ;
Adini, Irit ;
Pravda, Elke ;
Nahmias, Yaakov ;
Koirala, Samir ;
Corfas, Gabriel ;
D'Amato, Robert J. ;
Folkman, Judah .
NATURE BIOTECHNOLOGY, 2008, 26 (07) :799-807
[3]   Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues [J].
Brambilla, Davide ;
Le Droumaguet, Benjamin ;
Nicolas, Julien ;
Hashemi, S. Hossein ;
Wu, Lin-Ping ;
Moghimi, S. Moein ;
Couvreur, Patrick ;
Andrieux, Karine .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (05) :521-540
[4]   New Method Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF) to Monitor Interaction between Nanoparticles and the Amyloid-β Peptide [J].
Brambilla, Davide ;
Verpillot, Romain ;
Taverna, Myriam ;
De Kimpe, Line ;
Le Droumaguet, Benjamin ;
Nicolas, Julien ;
Canovi, Mara ;
Gobbi, Marco ;
Mantegazza, Francesco ;
Salmona, Mario ;
Nicolas, Valerie ;
Scheper, Wiep ;
Couvreur, Patrick ;
Andrieux, Karine .
ANALYTICAL CHEMISTRY, 2010, 82 (24) :10083-10089
[5]   The role of amyloid β peptide 42 in Alzheimer's disease [J].
Findeis, Mark A. .
PHARMACOLOGY & THERAPEUTICS, 2007, 116 (02) :266-286
[6]   'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG):: influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption [J].
Gref, R ;
Lück, M ;
Quellec, P ;
Marchand, M ;
Dellacherie, E ;
Harnisch, S ;
Blunk, T ;
Müller, RH .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2000, 18 (3-4) :301-313
[7]   BIODEGRADABLE LONG-CIRCULATING POLYMERIC NANOSPHERES [J].
GREF, R ;
MINAMITAKE, Y ;
PERACCHIA, MT ;
TRUBETSKOY, V ;
TORCHILIN, V ;
LANGER, R .
SCIENCE, 1994, 263 (5153) :1600-1603
[8]   Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β-amyloid and tau protein [J].
Panza, Francesco ;
Solfrizzi, Vincenzo ;
Frisardi, Vincenza ;
Imbimbo, Bruno P. ;
Capurso, Cristiano ;
D'Introno, Alessia ;
Colacicco, Anna M. ;
Seripa, Davide ;
Vendemiale, Gianluigi ;
Capurso, Antonio ;
Pilotto, Alberto .
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2009, 21 (06) :386-406
[9]  
Pierson L.-A., 2009, J NANONEUROSCI, V1, P174
[10]   MECHANISMS OF DISEASE Alzheimer's Disease [J].
Querfurth, Henry W. ;
LaFerla, Frank M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (04) :329-344